Skip to content
#gene editing Open access

Development of CRISPR_SCD001, an Autologous Hematopoietic Stem Cell Gene Therapy for Sickle Cell Disease after CRISPR-Cas9 Mediated Correction.

Sep 2026 · Molecular Therapy · 0 citations
Medicine

TL;DR

Data support initiation of a first-in-human phase I trial of CRISPR_SCD001 for sickle patients presenting with severe pathology, and generates a clinical-grade, cryopreserved CD34+ cell product that corrects the sickle mutation, restores anti-sickling hemoglobins, and meets pre-clinical safety criteria.

Abstract

We developed CRISPR_SCD001, an autologous cellular therapy in which the pathogenic HBB sickle allele is corrected by CRISPR-Cas9-mediated homology-directed repair using a single-stranded oligodeoxyribonucleotide as DNA donor template. The Drug Product (DP) from Plerixafor-mobilized peripheral-blood CD34+ cells from sickle and healthy donors were used for: 1) pharmacodynamic assessments to interrogate therapeutic potential; 2) evaluation of genotoxicity; and 3) in vivo characterization by a non-GLP toxicology study in NBSGW mice. Large-scale DP lots yielded 89 ± 5 % CD34+ purity with 84 ± 6 % viability. Mean gene correction at HBB was 22 ± 4 % of alleles, with 51 ± 6 % of allelic disruption. Edited erythroid cultures produced 39 ± 5 % adult hemoglobin and 40 ± 6 % fetal hemoglobin, reducing sickle hemoglobin from 89% to 22 ± 6 %. In NBSGW mice, CRISPR_SCD001 engrafted robustly (59 ± 25%), maintained editing frequencies comparable to injected cells (∼20% gene correction), showed polyclonal distribution of the edited cells, and no noteworthy treatment-related toxicity or pathologic evident were found by a blinded histopathology assessment. Our protocol generates a clinical-grade, cryopreserved CD34+ cell product that corrects the sickle mutation, restores anti-sickling hemoglobins, and meets pre-clinical safety criteria, establishing a reproducible manufacturing process suitable for clinical translation. These data support initiation of a first-in-human phase I trial of CRISPR_SCD001 for sickle patients presenting with severe pathology.

Read PDF

Similar papers

#gene editing Review Open access Sep 2026

A Comprehensive Review on Stem Cell Therapy and CRISPR/Cas Technology in the Treatment of Thalassemia

A variety of research is synthesized, examining the therapeutic potential of stem cell therapy and CRISPR/Cas technology in the treatment of thalassemia, highlighting the use of stem cell therapy and CRISPR/Cas gene editing technology as alternative treatment options.

Shreya Nair · 0 citations
#gene editing Review Sep 2026

CRISPR-Based Mediated Reactivation of Fetal Hemoglobin as a Therapeutic Strategy for Hemoglobinopathies: Evidence from Preclinical to Clinical Trials in Sickle Cell Disease and β-Thalassemia.

Overall, the available evidence suggests that CRISPR-based HbF reactivation is a promising therapeutic approach for β-hemoglobinopathies, although long-term efficacy and safety data remain necessary.

Daniel Antonio Wong Castro, Amelie Camille Morocho Perugachi, Marco Orlando Fuel Herrera · 0 citations
Review Open access Sep 2026

Clinical translation of CRISPR-Cas9 therapeutics in cancer and inherited genetic disorders

This review was developed following a structured literature search of major biomedical databases and clinical trial registries to synthesize current evidence on the therapeutic applications of CRISPR-Cas9 in oncology and inherited genetic disorders.

K. Bashir, P. Vasudev, Vikas Chhetri et al. · 0 citations
#gene editing Open access Sep 2026

In vivo HSPC gene therapy of hemoglobinopathies without drug selection of corrected cells

In vitro studies in an erythroid progenitor cell line and primary CD34+ cells demonstrated that the EPORW439* variant conferred a strong proliferative advantage to therapeutically modified erythroid progenitors, establishing a strategy to amplify the therapeutic benefit of otherwise limited in vivo HSPC gene editing fo...

Akshara Sakunthala Velmurugan, K. Paschoudi, Jack A. Queenan et al. · 0 citations
2016

Adenine Base Editor ABE7.10 Corrects Sickle Cell Disease HBB E6V Mutation in Patient-Derived Hematopoietic Stem Cells With >84% Editing Efficiency and Preserved Engraftment

These findings contribute empirically to hematology and genome editing and carry actionable implications for the design of programs and policies targeting SCD gene therapy clinical translation, base editing HSPC platform for hemoglobinopathies, and off-target safety framework for clinical-grade base editor development.

Maya T. Goldstein, Emeka Okafor, Lars K. Andersen · 0 citations
#gene editing Oct 2026

A Meta-Analysis of Animal Experiments on CRISPR-Cas9 Gene Editing for Hereditary Blood Disorders: Efficacy Assessment and Challenges in Hematopoietic System Reconstitution

CRISPR-Cas9 has demonstrated high initial editing efficiency in animal models of inherited hematological disorders and has successfully produced phenotypic improvements, manifested as an increased percentage of red blood cells in mice after transplantation, suggesting its potential therapeutic prospects for correcting...

Qiong-Wen Xu · 0 citations

Related blog posts

Microsoft Research Blog Nov 12, 2026

Microsoft Research Focus – Edition #98

What's new in research at Microsoft? Host Anson Ho explores the latest, including AI-powered universal translation, a breakthrough in a 31-year-old mathematics challenge, and advances making AI coding agents faster and more efficient.  The post Microsoft Research Focus – Edition #98 appeared first on Microsoft Research.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.